Dataene fra de to hovedundersøgelser samt understøttende data fra den åbne, udvidede undersøgelse og den komparative undersøgelse med omeprazol og misoprostol understøtter indikationen "behandling af NSAID- relaterede godartede gastriske og duodenale ulcera hos patienter, der kræver fortsat NSAID- behandling".
The data from the 2 pivotal studies as well as supportive data from the open-label extension study and the comparative study with omeprazole and misoprostol, support the indication: “Treatment of NSAID associated benign gastric and duodenal ulcers in patients requiring continued NSAID treatment”.